Last reviewed · How we verify
NCT07318675
A Randomized, Double-Blind, Placebo-Controlled, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HW211026 Ointment After Single or Multiple Doses in Subjects With Actinic Keratosis
Phase 1 trial testing HW211026 in Actinic Keratosis (AK) in 40 participants. Currently enrolling.
1 March 2026
Quick facts
| Lead sponsor | Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 25 December 2025 |
| Primary completion | 1 March 2026 |
| Estimated completion | 1 March 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- HW211026 — full drug profile →
- Placebo
Conditions studied
- Actinic Keratosis (AK) — all drugs for Actinic Keratosis (AK) →
Sponsor
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. — full company profile →
Who can join
18 and older, any sex, with Actinic Keratosis (AK). Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
The number and severity of treatment emergent adverse events (TEAEs)
Time frame: up to 28 days
To assess the safety and tolerability of single or multiple topical doses of HW211026 in adults with actinic keratosis
Sponsor's own description
This is a phase Ib study to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) characteristics of HW211026 ointment after single or multiple topical administrations in patients with actinic keratosis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07318675
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Actinic Keratosis (AK)
Currently open trials in the same condition.
- NCT06648447 — Investigation of the Efficacy and Tolerability of Topical Applied Tirbanibulin on Actinic Keratoses With Downward-direct · recruiting
Other Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. trials
Trials by the same sponsor.
- NCT07483489 — A Phase 2 Study of HW091077 in Participants With Refractory Chronic Cough Or Unexplained Chronic Cough (RCC/UCC). · Phase 2 · not yet recruiting
- NCT07493031 — A PhaseⅠ Study of HW252001 in Healthy Subjects · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07318675 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
- Last refreshed: 4 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07318675.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing